182 related articles for article (PubMed ID: 24486585)
1. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.
Huang J; Hu W; Bottsford-Miller J; Liu T; Han HD; Zand B; Pradeep S; Roh JW; Thanapprapasr D; Dalton HJ; Pecot CV; Rupaimoole R; Lu C; Fellman B; Urbauer D; Kang Y; Jennings NB; Huang L; Deavers MT; Broaddus R; Coleman RL; Sood AK
Clin Cancer Res; 2014 Apr; 20(7):1846-55. PubMed ID: 24486585
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
Wu Y; Huang J; Ivan C; Sun Y; Ma S; Mangala LS; Fellman BM; Urbauer DL; Jennings NB; Ram P; Coleman RL; Hu W; Sood AK
Gynecol Oncol; 2021 Oct; 163(1):181-190. PubMed ID: 34391578
[TBL] [Abstract][Full Text] [Related]
3. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
[TBL] [Abstract][Full Text] [Related]
4. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
Chang Q; Jorgensen C; Pawson T; Hedley DW
Br J Cancer; 2008 Oct; 99(7):1074-82. PubMed ID: 18797457
[TBL] [Abstract][Full Text] [Related]
5. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
6. Serine 897 Phosphorylation of EPHA2 Is Involved in Signaling of Oncogenic ERK1/2 Drivers in Thyroid Cancer Cells.
Allocca C; Cirafici AM; Laukkanen MO; Castellone MD
Thyroid; 2021 Jan; 31(1):76-87. PubMed ID: 32762307
[No Abstract] [Full Text] [Related]
7. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.
Caccia D; Miccichè F; Cassinelli G; Mondellini P; Casalini P; Bongarzone I
Mol Cancer; 2010 Oct; 9():278. PubMed ID: 20955590
[TBL] [Abstract][Full Text] [Related]
9. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
Rebocho AP; Marais R
Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
[TBL] [Abstract][Full Text] [Related]
10. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
Sen B; Peng S; Tang X; Erickson HS; Galindo H; Mazumdar T; Stewart DJ; Wistuba I; Johnson FM
Sci Transl Med; 2012 May; 4(136):136ra70. PubMed ID: 22649091
[TBL] [Abstract][Full Text] [Related]
11. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Congleton J; MacDonald R; Yen A
Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
[TBL] [Abstract][Full Text] [Related]
12. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
[TBL] [Abstract][Full Text] [Related]
13. Analyses of the oncogenic BRAF
Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
[TBL] [Abstract][Full Text] [Related]
14. Src inhibitors in suppression of papillary thyroid carcinoma growth.
Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
[TBL] [Abstract][Full Text] [Related]
15. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
16. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R; Mesa T; Vultur A; Lee F; Jove R
Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
[TBL] [Abstract][Full Text] [Related]
18. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Wu Z; Doondeea JB; Gholami AM; Janning MC; Lemeer S; Kramer K; Eccles SA; Gollin SM; Grenman R; Walch A; Feller SM; Kuster B
Mol Cell Proteomics; 2011 Dec; 10(12):M111.011635. PubMed ID: 21955398
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
20. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
